The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass: A Randomized Trial
Abstract
CONTEXT: Inflammation and ischemia-reperfusion injury during coronary artery bypass graft (CABG) surgery requiring cardiopulmonary bypass are associated with postoperative myocardial infarction (MI) and mortality. OBJECTIVE: To determine the efficacy and safety of pexelizumab, a C5 complement inhibitor, in reducing perioperative MI and mortality in CABG surgery. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial, including 3099 patients (> or = 18 years) undergoing CABG surgery with or without valve surgery at 205 hospitals in North America and Western Europe from January 2002 to February 2003. INTERVENTIONS: Patients were randomly assigned to receive intravenous pexelizumab (2.0 mg/kg bolus plus 0.05 mg/kg per hour for 24 hours; n = 1553) or placebo (n = 1546) 10 minutes before undergoing the procedure. MAIN OUTCOME MEASURES: The primary composite end point was the incidence of death or MI within 30 days of randomization in those undergoing CABG surgery only (n = 2746). Secondary analyses included the intent-to-treat analyses of death or MI composite at days 4 and 30 in all 3099 study patients. RESULTS: After 30 days, 134 (9.8%) of 1373 of patients receiving pexelizumab vs 161 (11.8%) of 1359 of patients receiving placebo (relative risk, 0.82; 95% confidence interval, 0.66-1.02; P =.07) died or experienced MI in the CABG surgery only population. In the intent-to-treat analyses, 178 (11.5%) of 1547 patients receiving pexelizumab vs 215 (14.0%) of 1535 receiving placebo died or experienced MI (relative risk, 0.82; 95% confidence interval, 0.68-0.99; P =.03). The trial was not powered to detect a reduction in mortality alone. CONCLUSIONS: Compared with placebo, pexelizumab was not associated with a significant reduction in the risk of the composite end point of death or MI in 2746 patients who had undergone CABG surgery only but was associated with a statistically significant risk reduction 30 days after the procedure among all 3099 patients undergoing CABG with or without valve surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chenoweth, D. E., Cooper, S. W., Hugli, T. E., Stewart, R. W., Blackstone, E. H., & Kirklin, J. W. (1981) · New England Journal of Medicine · doi:10.1056/nejm198102263040901 · Cited by 1,146
Are you awake? Cognitive performance and reverie during the hypnopompic state
Dinges, D. F. (2004) · Sleep and cognition. · doi:10.1037/10499-012 · Cited by 124
Cited by
Ischemia and reperfusion—from mechanism to translation
Eltzschig, H. K., & Eckle, T. (2011) · Nature Medicine · doi:10.1038/nm.2507 · Cited by 3,382
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Whitlock, R. P., Devereaux, P. J., Teoh, K. H., Lamy, A., Vincent, J., Pogue, J., Paparella, D., Sessler, D. I., Karthikeyan, G., Villar, J. C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00273-1 · Cited by 368
The systemic inflammatory response syndrome and cardiopulmonary bypass
Day, J. R. S., & Taylor, K. M. (2005) · International Journal of Surgery · doi:10.1016/j.ijsu.2005.04.002 · Cited by 254
Self-citationRadial Artery and Saphenous Vein Patency More Than 5 Years After Coronary Artery Bypass Surgery
Deb, S., Cohen, E. A., Singh, S. K., Une, D., Laupacis, A., & Fremes, S. E. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.037 · Cited by 253
Metadata
- Authors
- Verrier, E. D., Shernan, S. K., Taylor, K. M., Van de Werf, F., Newman, M. F., Chen, J. C., Carrier, M., Haverich, A., Malloy, K. J., Adams, P. X., Todaro, T. G., Mojcik, C. F., Rollins, S. A., Levy, J. H., & for the PRIMO-CABG Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-05-19
- Volume
- 291
- Issue
- 19
- Pages
- 2319
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2116638495
- Cited by
- 191
- References
- 2
- FWCI
- 18.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass: A Randomized Trial. https://app.cochat.ai/papers/10.1001/jama.291.19.2319
- The paper
- Verrier, E. D., Shernan, S. K., Taylor, K. M., Van de Werf, F., Newman, M. F., Chen, J. C., Carrier, M., Haverich, A., Malloy, K. J., Adams, P. X., Todaro, T. G., Mojcik, C. F., Rollins, S. A., Levy, J. H., & for the PRIMO-CABG Investigators. (2004). Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass: A Randomized Trial. JAMA. https://doi.org/10.1001/jama.291.19.2319
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.